Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9BT22: Variant p.Ile209Ser

Chitobiosyldiphosphodolichol beta-mannosyltransferase
Gene: ALG1
Feedback?
Variant information Variant position: help 209 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Isoleucine (I) to Serine (S) at position 209 (I209S, p.Ile209Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (I) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CDG1K; decreased function in protein glycosylation as shown by rescue assays in an ALG1-deficient yeast strain. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 209 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 464 The length of the canonical sequence.
Location on the sequence: help SHLNLCVTNAMREDLADNWH I RAVTVYDKPASFFKETPLDL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         SHLNLCVTNAMREDLADNWHIR---AVTVYDKPASFFKETPLDL

Mouse                         SHLNLCVTNAMREDLAENWCVR---AVTLYDKPASFFKETP

Slime mold                    AYAHLFVTNEMKIQLVRDWNLKGK-TFVFHDKASPIFK-SL

Baker's yeast                 ADYNLTVTEAMRKYLIQSFHLNPKRCAVLYDRPASQFQPLA

Fission yeast                 AYAHLTVSKRMK-DVLQTWGMNP--CYVCYDRPPNHF--TP
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 464 Chitobiosyldiphosphodolichol beta-mannosyltransferase
Topological domain 24 – 464 Lumenal



Literature citations
ALG1-CDG: Clinical and Molecular Characterization of 39 Unreported Patients.
Ng B.G.; Shiryaev S.A.; Rymen D.; Eklund E.A.; Raymond K.; Kircher M.; Abdenur J.E.; Alehan F.; Midro A.T.; Bamshad M.J.; Barone R.; Berry G.T.; Brumbaugh J.E.; Buckingham K.J.; Clarkson K.; Cole F.S.; O'Connor S.; Cooper G.M.; Van Coster R.; Demmer L.A.; Diogo L.; Fay A.J.; Ficicioglu C.; Fiumara A.; Gahl W.A.; Ganetzky R.; Goel H.; Harshman L.A.; He M.; Jaeken J.; James P.M.; Katz D.; Keldermans L.; Kibaek M.; Kornberg A.J.; Lachlan K.; Lam C.; Yaplito-Lee J.; Nickerson D.A.; Peters H.L.; Race V.; Regal L.; Rush J.S.; Rutledge S.L.; Shendure J.; Souche E.; Sparks S.E.; Trapane P.; Sanchez-Valle A.; Vilain E.; Voello A.; Waechter C.J.; Wang R.Y.; Wolfe L.A.; Wong D.A.; Wood T.; Yang A.C.; Matthijs G.; Freeze H.H.;
Hum. Mutat. 37:653-660(2016)
Cited for: INVOLVEMENT IN CDG1K; FUNCTION; VARIANTS CDG1K ARG-50; PHE-71; LEU-74; VAL-88; LEU-98; PHE-114; ARG-150; SER-209; LEU-258; TRP-276; PHE-281; GLY-289; VAL-291; ASP-353; ARG-358; LEU-359; VAL-360; ALA-363; GLN-366; GLN-367; LYS-382; ARG-384; SER-388 AND TRP-438; CHARACTERIZATION OF VARIANTS CDG1K ARG-50; PHE-71; LEU-74; VAL-88; LEU-98; PHE-114; ARG-150; SER-209; LEU-258; TRP-276; PHE-281; GLY-289; VAL-291; ASP-353; ARG-358; LEU-359; VAL-360; ALA-363; GLN-366; GLN-367; LYS-382; ARG-384; SER-388 AND TRP-438; CHARACTERIZATION OF VARIANT ASN-267;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.